Drug Discovery Weekly — April 14, 2026

FDA & Regulatory Updates

1. Travere's Filspari Earns FDA's First FSGS Approval Travere Therapeutics secured a landmark decision when the FDA granted approval for Filspari (sparsentan) in focal segmental glomerulosclerosis (FSGS) — making it the first-ever FDA-approved treatment for the rare kidney disease. The approval follows a string of recent positive FDA decisions in rare disease, including Denali's Hunter syndrome drug Avlayah and Rocket's gene therapy Kresladi. This FSGS nod reinforces a broader momentum in orphan drug development.

2. FDA Approves Generics for AstraZeneca's Farxiga (Dapagliflozin) The FDA regulatory tracker confirmed approval of generic versions of AstraZeneca's Farxiga (dapagliflozin), the SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. The entry of generics is expected to significantly reshape the competitive landscape for the SGLT2 class.

3. Replimune Faces Second FDA Rejection for Melanoma Therapy, Plans Staff Layoffs Replimune received a second FDA refusal for its melanoma prospect — described by the company as "disappointing" — and announced layoffs following the setback. The repeated rejection underscores the challenging regulatory pathway for oncolytic viral therapies in competitive oncology indications.

4. HHS Updates ACIP Charter with New Vaccine Safety Emphasis Following a legal setback, HHS updated the Advisory Committee on Immunization Practices (ACIP) charter to place greater emphasis on vaccine safety. The revision reflects ongoing tensions between the Kennedy-led HHS and traditional vaccine policy frameworks.

Clinical Trial Milestones

1. Lilly's Jaypirca (Pirtobrutinib) Wins Phase 3 CLL Trial with Fixed-Duration Regimen Eli Lilly announced positive Phase 3 results for Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia (CLL), demonstrating the drug's efficacy as a fixed-duration treatment — a format the company characterized as "ambitious." The non-covalent BTK inhibitor's ability to show durable responses in a time-limited treatment regimen could differentiate it from competitors in the increasingly crowded BTK inhibitor market.

2. Vanda Initiates Phase 3 Trial of Nereus for GLP-1 Users Vanda Pharmaceuticals has kicked off a Phase 3 trial evaluating Nereus, its motion sickness drug, specifically in patients taking GLP-1 receptor agonist therapies (such as semaglutide or tirzepatide). The study targets the prevention of vomiting — a known side effect of GLP-1 treatments — representing a creative indication expansion strategy riding the GLP-1 wave.

3. GSK Presents Phase 2 Data for B7-H4-Targeted ADC in Gynaecological Cancers GSK presented promising early efficacy and safety data for its B7-H4-targeted antibody-drug conjugate in gynaecological cancers, supporting the initiation of five pivotal Phase 3 trials in 2026. The data affirm growing industry interest in B7-H4 as an actionable target in solid tumors.

Deals & Pipeline Moves

1. Regeneron Enters Radiopharmaceuticals via $2.1B Biobucks Deal with Australia's Telix In one of the week's highest-profile strategic moves, Regeneron announced a partnership with Australian radiopharmaceutical company Telix valued at up to $2.1 billion in biobucks. The deal marks Regeneron's entry into the fast-growing radiopharmaceuticals space — a sector attracting intense attention following Eli Lilly's acquisition of Point Biopharma and Bristol Myers Squibb's RayzeBio deal.

2. Garda Therapeutics Acquires Assertio and Rolvedon for $125M Garda Therapeutics completed the acquisition of Assertio Therapeutics and its chemotherapy supportive care drug Rolvedon (eflapegrastim) — used to prevent chemotherapy-induced neutropenia — for $125.1 million. The deal gives Garda an established commercial-stage asset in oncology supportive care.

3. AbbVie Sues Over "Outdated" 340B Drug Discount Program Guidance AbbVie filed a new lawsuit challenging what it calls "outdated" guidance governing the federal 340B drug discount program — escalating pharma's long-running effort to reform or restrict the program. The legal action follows similar challenges from other manufacturers and arrives amid heightened policy scrutiny of 340B pricing dynamics.

Analysis: Week in Perspective

Rare Disease Takes Center Stage — and the Competitive Stakes Are Rising

Travere's Filspari approval as the FDA's first-ever treatment for FSGS is this week's defining moment — not just because of its standalone significance to the ~5,400 patients diagnosed annually in the U.S., but because it epitomizes a broader strategic trend reshaping the industry.

The approval arrives alongside other recent rare disease wins (Denali's Avlayah for Hunter syndrome, Rocket's Kresladi gene therapy), creating what appears to be a deliberate pattern: the FDA is actively rewarding developers who pursue indications with unmet medical needs, robust biological rationale, and patient populations that traditional clinical trial frameworks struggle to serve.

For Travere, the FSGS approval is particularly significant because it followed a "disappointing" Phase 3 ASHES trial result — demonstrating that regulatory persistence and creative trial design can still yield approvals even when pivotal data miss on traditional endpoints. This aligns with the FDA's stated interest in single-trial approvals and flexible evidence standards for rare indications.

The week's other big story — Regeneron's $2.1B radiopharmaceuticals move with Telix — deserves equal attention. The deal cements radiopharmaceuticals as one of the industry's most crowded emerging sectors, with Eli Lilly, BMS, Novartis, and now Regeneron all staking claims. The key question going forward: can clinical differentiation be demonstrated in a space where targeted isotope delivery is rapidly commoditizing, or will competitive advantage shift to manufacturing scale, intellectual property around targeting vectors, and isotope supply chains?

Meanwhile, Lilly's Jaypirca Phase 3 win in CLL with fixed-duration treatment reflects the next battleground in BTK inhibitors — not just whether drugs work, but how they're administered. Fixed-duration regimens reduce treatment burden and cost, and in a market where patients often take BTK inhibitors indefinitely, clinical proof of comparable outcomes with time-limited therapy represents a meaningful commercial differentiator.

What to Watch Next

1. FDA PDUFA Dates — May 2026 Pipeline: The Psychiatry Advisor reports that FDA decisions in May 2026 are expected across ADHD, Alzheimer's disease, breast cancer, diabetes, and myasthenia gravis indications. Watch for readouts on several high-stakes NDA reviews.

2. Q2 2026 FDA Decision Calendar: Seven key FDA decisions are flagged for Q2 2026, including datopotamab deruxtecan (Dato-DXd) in triple-negative breast cancer and Orca-T in blood cancers — both with potential to transform standard of care in highly competitive settings.

3. Revolution Medicines RAS Inhibitor — Pancreatic Cancer Data: Fresh Phase 3 data published just this week show daraxonrasib extending survival in previously treated metastatic pancreatic adenocarcinoma — the first RAS inhibitor to demonstrate this benefit. Expect regulatory discussions and a potential NDA filing timeline to emerge in coming weeks.

4. Varegacestat Phase 3 Results — Desmoid Tumors: Varegacestat just hit its Phase 3 PFS endpoint in progressing desmoid tumors, according to OncLive — setting the stage for an NDA submission and potential FDA review later in 2026 for this rare soft-tissue sarcoma.

5. Fierce Pharma Engage Conference (April 22–24, San Diego): The annual commercial pharma conference convenes next week with expected discussion of portfolio strategy, HHS policy changes under the Kennedy administration, and the competitive dynamics reshaping rare disease and oncology markets.